Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Schizophrenia Clinical Trial

Official title:

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06041646
• Other study ID #: BXCL501-404
• Status: Recruiting
• Phase: Phase 4
• Start date: October 12, 2023
• Est. completion date: April 2024

Study information

• Verified date: December 2023
• Source: BioXcel Therapeutics Inc
• Contact: Bethann DeGeronimo, MS
• Phone: 203-710-4215
• Email: bdegeronimo[@]bioxceltherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.

Description:

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females (18 to 65 years old, inclusive) with agitation associated with schizophrenia or bipolar disorder. Subjects will be screened for eligibility within 15 days of first dose and no study procedures will occur unless subjects provide written informed consent. Subjects will receive single doses of 180 μg of Igalmi as needed for the treatment of agitation over a period of 7 days followed by a 3- day follow-up period during which time no Igalmi will be administered in an effort to characterize any potential withdrawal. Subjects will sublingually self-administer Igalmi for an agitation episode that reaches a pre-dose PEC total score of 14 or greater, as determined by a trained rater. Safety assessments will be conducted before and after each dose. If the subject's agitation is recurrent or persistent, repeat doses of 90 µg may be administered (no more than 2 repeat doses within a 24-hour period) in the absence of any safety concerns or adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male and female subjects between the ages of 18 to 65 years, inclusive.

2. Subjects who have met DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder or bipolar I or II disorder.

3. Subjects who are currently moderate to severely agitated at least 3 days a week.

4. Subjects who read, understand, and provide written informed consent.

5. Subjects who are in good general health prior to study participation as determined by a detailed medical history and in the opinion of the Principal Investigator.

6. Subjects who agree to use a medically acceptable and effective birth control method

7. Subjects must be willing to remain in-clinic for the duration of the study.

Exclusion Criteria:

1. Subjects with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse during screening.

2. Use of benzodiazepines or other hypnotics or antipsychotic drugs in the 6 hours before study treatment.

3. Subjects with congenital prolonged QT syndrome.

4. Prior treatment with Igalmi

Related Conditions & MeSH terms

• Agitation,Psychomotor
• Bipolar Disorder
• Mood Disorders
• Psychomotor Agitation
• Psychotic Disorders
• Schizo Affective Disorder
• Schizophrenia
• Schizophreniform Disorders

Intervention

Drug:
• Sublingual film containing Igalmi
Sublingual film containing 180 µg of Igalmi (dexmedetomidine)

Locations

Country	Name	City	State
United States	BioXcel Clinical Research Site	Little Rock	Arkansas
United States	BioXcel Clinical Research Site	Rogers	Arkansas

Sponsors (2)

Lead Sponsor	Collaborator
BioXcel Therapeutics Inc	Lotus Clinical Research, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score	The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).	Baseline and 2 hours post-dose for all doses administered
Primary	Clinical Global Impression - Improvement (CGI-I)	The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.	2 hours post-dose for all doses administered
Secondary	Incidence of Adverse Events During the Follow-up Period	Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on =2 consecutive days of the 3-day off-treatment follow-up period.	Day 8 through Day 10